Loading…
Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer
With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external be...
Saved in:
Published in: | Frontiers in oncology 2014, Vol.4, p.214-214 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53 |
---|---|
cites | cdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53 |
container_end_page | 214 |
container_issue | |
container_start_page | 214 |
container_title | Frontiers in oncology |
container_volume | 4 |
creator | Vargo, John A Ferris, Robert L Clump, David A Heron, Dwight E |
description | With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer.
Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R).
Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains.
Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL. |
doi_str_mv | 10.3389/fonc.2014.00214 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d12e7e9717194d9cb05206df087bd26f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d12e7e9717194d9cb05206df087bd26f</doaj_id><sourcerecordid>1557082643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</originalsourceid><addsrcrecordid>eNpVkc9PHCEcxUnTphr17K3h2Muu_BxmLk0a01YTkx5qE2-EH19c7OwwBbZm__uy7mqUC_B4fODlIXROyZLzfrgIaXJLRqhYEsKoeIeOGeNiMQh-9_7V-gidlfJA2ugkoYR_REdMUqk4747R468KGVI1rkaHbfJbnI2Pqa4gm3mLTcFzjmuTt7hmMHUNU8UhZQyjhzxu8WxqbFrBj7Gu8Bp8dGZsepzS3BB2BLwC47GZPJ7A_cHOTA7yKfoQzFjg7DCfoN_fv91eXi1ufv64vvx6s3BcCbEAZ6HjVDHrh4GJtguOguotF9I6q7gMvBN-UEZ6RwXjzA_EBSqDBd-B5Cfoes_1yTzoQxSdTNRPQsr32uQWfQTtKQMFg6KKDg3pLJGMdD6QXlnPutBYX_aseWNbUNdiZzO-gb49meJK36d_WlDWM6oa4PMBkNPfDZSq17E4GEczQdoUTaVUpGed4M16sbe6nErJEF6eoUTv2te79vWuff3Ufrvx6fXvXvzPXfP_7ryvNA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1557082643</pqid></control><display><type>article</type><title>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</title><source>PubMed Central</source><creator>Vargo, John A ; Ferris, Robert L ; Clump, David A ; Heron, Dwight E</creator><creatorcontrib>Vargo, John A ; Ferris, Robert L ; Clump, David A ; Heron, Dwight E</creatorcontrib><description>With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer.
Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R).
Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains.
Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2014.00214</identifier><identifier>PMID: 25157336</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>cetuximab ; elderly ; head and neck cancer ; Oncology ; radiosurgery ; SBRT</subject><ispartof>Frontiers in oncology, 2014, Vol.4, p.214-214</ispartof><rights>Copyright © 2014 Vargo, Ferris, Clump and Heron. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</citedby><cites>FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128217/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128217/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4021,27921,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25157336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vargo, John A</creatorcontrib><creatorcontrib>Ferris, Robert L</creatorcontrib><creatorcontrib>Clump, David A</creatorcontrib><creatorcontrib>Heron, Dwight E</creatorcontrib><title>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer.
Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R).
Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains.
Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL.</description><subject>cetuximab</subject><subject>elderly</subject><subject>head and neck cancer</subject><subject>Oncology</subject><subject>radiosurgery</subject><subject>SBRT</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc9PHCEcxUnTphr17K3h2Muu_BxmLk0a01YTkx5qE2-EH19c7OwwBbZm__uy7mqUC_B4fODlIXROyZLzfrgIaXJLRqhYEsKoeIeOGeNiMQh-9_7V-gidlfJA2ugkoYR_REdMUqk4747R468KGVI1rkaHbfJbnI2Pqa4gm3mLTcFzjmuTt7hmMHUNU8UhZQyjhzxu8WxqbFrBj7Gu8Bp8dGZsepzS3BB2BLwC47GZPJ7A_cHOTA7yKfoQzFjg7DCfoN_fv91eXi1ufv64vvx6s3BcCbEAZ6HjVDHrh4GJtguOguotF9I6q7gMvBN-UEZ6RwXjzA_EBSqDBd-B5Cfoes_1yTzoQxSdTNRPQsr32uQWfQTtKQMFg6KKDg3pLJGMdD6QXlnPutBYX_aseWNbUNdiZzO-gb49meJK36d_WlDWM6oa4PMBkNPfDZSq17E4GEczQdoUTaVUpGed4M16sbe6nErJEF6eoUTv2te79vWuff3Ufrvx6fXvXvzPXfP_7ryvNA</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Vargo, John A</creator><creator>Ferris, Robert L</creator><creator>Clump, David A</creator><creator>Heron, Dwight E</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2014</creationdate><title>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</title><author>Vargo, John A ; Ferris, Robert L ; Clump, David A ; Heron, Dwight E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>cetuximab</topic><topic>elderly</topic><topic>head and neck cancer</topic><topic>Oncology</topic><topic>radiosurgery</topic><topic>SBRT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vargo, John A</creatorcontrib><creatorcontrib>Ferris, Robert L</creatorcontrib><creatorcontrib>Clump, David A</creatorcontrib><creatorcontrib>Heron, Dwight E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vargo, John A</au><au>Ferris, Robert L</au><au>Clump, David A</au><au>Heron, Dwight E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2014</date><risdate>2014</risdate><volume>4</volume><spage>214</spage><epage>214</epage><pages>214-214</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer.
Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R).
Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains.
Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>25157336</pmid><doi>10.3389/fonc.2014.00214</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2234-943X |
ispartof | Frontiers in oncology, 2014, Vol.4, p.214-214 |
issn | 2234-943X 2234-943X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_d12e7e9717194d9cb05206df087bd26f |
source | PubMed Central |
subjects | cetuximab elderly head and neck cancer Oncology radiosurgery SBRT |
title | Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A39%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20body%20radiotherapy%20as%20primary%20treatment%20for%20elderly%20patients%20with%20medically%20inoperable%20head%20and%20neck%20cancer&rft.jtitle=Frontiers%20in%20oncology&rft.au=Vargo,%20John%20A&rft.date=2014&rft.volume=4&rft.spage=214&rft.epage=214&rft.pages=214-214&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2014.00214&rft_dat=%3Cproquest_doaj_%3E1557082643%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1557082643&rft_id=info:pmid/25157336&rfr_iscdi=true |